---
schema_version: "secwatch.filing_event.v1"
accession: "0001618835-22-000200"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2022-10-14T23:59:59+00:00"
generated_at: "2026-06-23T03:34:00.123924+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.35
calibrated_materiality_score: 0.35
confidence: "high"
source: SEC EDGAR
---

# Evofem General Counsel and Secretary resigns effective Oct 14, 2022

## Summary
- Alexander A. Fitzpatrick resigned as General Counsel and Secretary on October 10, 2022.
- Resignation effective October 14, 2022; no reason provided in the filing.
- No replacement or interim successor named in the 8-K.

## SEC filing metadata
- accession: 0001618835-22-000200
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2022-10-14T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.35
- calibrated_materiality_score: 0.35
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000161883522000200/0001618835-22-000200-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000161883522000200/evfm-20221010.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001618835-22-000200
- JSON: https://secwatch.observer/filing/0001618835-22-000200.json
- Plain text: https://secwatch.observer/filing/0001618835-22-000200.txt

## Key facts
- Executive change
  Alexander A. Fitzpatrick resigned as General Counsel and Secretary at Evofem Biosciences, Inc..
  - Action: resigned
  - Role: General Counsel and Secretary
  source text: On October 10, 2022, Alexander A. Fitzpatrick, the General Counsel and Secretary of Evofem Biosciences, Inc. (the “Company”) tendered his resignation to the Company, effective October 14, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1618835/000161883522000200/0001618835-22-000200-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.